An advisory committee to the Food and Drug Administration is recommending that the FDA grant accelerated approval to a GlaxoSmithKline drug for the treatment of Leukemia.

The chemotherapy drug Arranon would be used to treat children and adults with T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma.

The drug would be for use in patients who have not responded or have suffered a relapse following at least two regimens of chemotherapy.